| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/02/2006 | CA2569507A1 Amido compounds and their use as pharmaceuticals |
| 02/01/2006 | EP1621545A2 Oligoribonucleotides and ribonucleases for cleaving RNA |
| 02/01/2006 | EP1621544A1 Remedies for diseases caused by strengthened vascular smooth muscle using 14-membered ring macrolide compounds |
| 02/01/2006 | EP1621540A1 Nitrogen-containing heterocyclic compounds and use thereof |
| 02/01/2006 | EP1621539A1 Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
| 02/01/2006 | EP1621537A1 Five-membered heterocyclic derivative |
| 02/01/2006 | EP1621535A1 Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
| 02/01/2006 | EP1621533A1 Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents |
| 02/01/2006 | EP1621532A1 Fexofenadine base polymorphic forms |
| 02/01/2006 | EP1621219A2 Intraocular implants for preventing transplant rejection in the eye |
| 02/01/2006 | EP1621212A1 Formulations comprising antisense nucleotides to connexins |
| 02/01/2006 | EP1621210A1 Adiponectin production enhancer |
| 02/01/2006 | EP1621207A2 Mixture of defibrotide and G-CSF, and its use for activating haematopoietic progenitors |
| 02/01/2006 | EP1621204A1 Use of products derived from selenoprotein T in the context of calcium homeostasis |
| 02/01/2006 | EP1621202A1 Freeze-dried preparation containing methylcobalamin and process for producing the same |
| 02/01/2006 | EP1621201A1 Hesperidin for prophylaxis and treatment of diseases of the central nervous system, in particular Alzheimer's and Parkinson's diseases, for therapy after stroke as well as for chronic pain. |
| 02/01/2006 | EP1621200A1 Pharmaceutical combinations containing an inhibitor of platelet aggregation and a fibrate |
| 02/01/2006 | EP1621199A1 Remedies for diseases to be applied to eye |
| 02/01/2006 | EP1621198A2 Substituted carbostyril derivatives as 5-HT 1A receptor subtype agonists |
| 02/01/2006 | EP1621197A2 Composition comprising a steroid and an anticholinergic agent |
| 02/01/2006 | EP1621196A1 Therapeutic and/or preventive agent for chronic skin disease |
| 02/01/2006 | EP1621195A2 The use of pyridinic NK-1 receptor antagonists for the treatment of brain, spinal or nerve injury |
| 02/01/2006 | EP1621194A1 Active oxygen eliminator originating in natural material and use of the same |
| 02/01/2006 | EP1621193A2 Treatment of non-painful bladder disorders using alpha2-delta-subunit calcium channel modulators |
| 02/01/2006 | EP1621192A1 Transdermal drug delivery formulations with optimal amounts of vasodilators therein |
| 02/01/2006 | EP1621191A1 Treatment of inflammatory diseases by RXR Antagonists |
| 02/01/2006 | EP1621190A1 Deprenyl compounds for treating Multiple Sclerosis |
| 02/01/2006 | EP1621189A2 Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function |
| 02/01/2006 | EP1621188A1 Ultraviolet-shielding type patch |
| 02/01/2006 | EP1621186A1 Modafinil oral lyophilizate |
| 02/01/2006 | EP1621077A1 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| 02/01/2006 | EP1621076A1 Synergistic microbicidal combination |
| 02/01/2006 | EP1620564A2 Methods of treating diseases responsive to induction of apoptosis and screening assays |
| 02/01/2006 | EP1620562A2 Modulation of telomere-initiated cell signaling |
| 02/01/2006 | EP1620560A1 Delivery of sirna to cells using polyampholytes |
| 02/01/2006 | EP1620545A2 Disease prevention and vaccination following thymic reactivation |
| 02/01/2006 | EP1620544A2 MODIFIED iRNA AGENTS |
| 02/01/2006 | EP1620469A2 Improved extration and purification method for cereal beta (1-3) beta (1-4) glucan |
| 02/01/2006 | EP1620450A2 Polymeric oligonucleotide prodrugs |
| 02/01/2006 | EP1620445A2 Method and compositions for identifying anti-hiv therapeutic compounds |
| 02/01/2006 | EP1620435A1 IMADAZOPYRIDINE COMPOUNDS HAVING 5-HT sb 4 /sb RECEPTOR AGONISTIC ACTIVITY AND 5-HT sb 3 /sb RECEPTOR ANTAGONISTIC ACTIVITY |
| 02/01/2006 | EP1620433A1 Oxazolidinone derivatives as antimicrobials |
| 02/01/2006 | EP1620429A1 Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| 02/01/2006 | EP1620428A1 Substituted pyrimidinones and pyrimidinthiones as crf antagonists |
| 02/01/2006 | EP1620426A1 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors |
| 02/01/2006 | EP1620425A1 Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists |
| 02/01/2006 | EP1620424A2 Improved jasmine aromachemicals |
| 02/01/2006 | EP1620419A2 Stabilized derivatives of ascorbic acid |
| 02/01/2006 | EP1620413A2 Compounds, compositions, and methods |
| 02/01/2006 | EP1620412A2 Heterocyclic compounds and hydro isomers thereof |
| 02/01/2006 | EP1620411A2 Inhibitors of akt activity |
| 02/01/2006 | EP1620409A1 Quinoxalin-3-one derivatives as orexin receptor antagonists |
| 02/01/2006 | EP1620407A2 Oxo-pyrimidine compounds |
| 02/01/2006 | EP1620406A2 1,2-diarylimidazoles useful as inhibitors of cox |
| 02/01/2006 | EP1620405A2 Pyrazole-amides and sulfonamides as sodium channel modulators |
| 02/01/2006 | EP1620400A1 Chemical compounds |
| 02/01/2006 | EP1620399A1 Indolone-acetamide derivatives, processes for preparing them and their uses |
| 02/01/2006 | EP1620391A2 Cyclic derivatives as modulators of chemokine receptor activity |
| 02/01/2006 | EP1620126A2 Disease prevention and vaccination prior to thymic reactivations |
| 02/01/2006 | EP1620125A2 Tolerance to graft following thymic reactivation |
| 02/01/2006 | EP1620114A2 Delivery systems of homogeneous thermoreversible low viscosity polymannan gum films |
| 02/01/2006 | EP1620113A1 Topical formulation of ivermectin for the treatment of dermatological conditions |
| 02/01/2006 | EP1620112A2 Desmoglein 4 is a novel gene involved in hair growth |
| 02/01/2006 | EP1620111A2 Controlled release formulation of erythromycin derivatives |
| 02/01/2006 | EP1620110A2 Immunomodulator phosphonate conjugates |
| 02/01/2006 | EP1620109A2 Kinase inhibitor phosphonate conjugates |
| 02/01/2006 | EP1620108A2 Pyrazole-amine compounds useful as kinase inhibitors |
| 02/01/2006 | EP1620107A1 Method of improved diuresis in individuals with impaired renal function |
| 02/01/2006 | EP1620103A1 Combinations comprising anti-epileptic drugs for the treatment of neurological disorders |
| 02/01/2006 | EP1620102A2 3-(1-naphthyl)-2-cyanopropanoic acid derivatives as estrogen receptor ligands |
| 02/01/2006 | EP1620101A2 Polymorphs of cabergoline |
| 02/01/2006 | EP1620099A1 Use of irinotecan for treatment of resistant breast cancer |
| 02/01/2006 | EP1620098A1 Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections |
| 02/01/2006 | EP1620097A1 Prophylactic pretreatment with antioxidants |
| 02/01/2006 | EP1620096A2 Pellet formulations of acid-labile antiulcer benzimidazole compounds |
| 02/01/2006 | EP1620095A2 Inhibitors of akt activity |
| 02/01/2006 | EP1620094A2 Novel chemical compounds |
| 02/01/2006 | EP1620093A2 Pesticidal (dihalopropenyl) phenylalkyl substituted benzoxazole and benzothiazole derivatives |
| 02/01/2006 | EP1620092A2 Compounds, compositions, and methods |
| 02/01/2006 | EP1620091A2 Inhibitors of glutaminyl cyclase |
| 02/01/2006 | EP1620088A2 Indole acetic acid derivatives and their use as pharmaceutical agents |
| 02/01/2006 | EP1620085A1 Use of phenoxyacetic acid derivatives for treating hyperactive bladder |
| 02/01/2006 | EP1620084A1 Use of kynurenine-3-hydroxylase inhibitors for the preparation of medicaments for the treatment of l-dopa induced movement disorders, dyskinesias, drug addiction, pain and cataract |
| 02/01/2006 | EP1620083A2 Combination therapies |
| 02/01/2006 | EP1620082A2 Medical use of inhibitors of glutaminyl and glutamate cyclases |
| 02/01/2006 | EP1620081A2 Treatment of incontinence with 5htc2 agonists |
| 02/01/2006 | EP1620080A1 Abuse-resistant transdermal dosage form |
| 02/01/2006 | EP1620079A1 Bone targeting of biodegradable drug-containing nanoparticles |
| 02/01/2006 | EP1620078A2 Biodegradable nanoparticles comprising an aminoglycoside and a polymer like a polysaccharide |
| 02/01/2006 | EP1620069A2 Warning and nonirritating lubricant fungicide compositions in the form of a gel |
| 02/01/2006 | EP1620066A2 Oral care methods and products |
| 02/01/2006 | EP1620063A1 Keratolytic composition with anti-allergic anti-inflammatory properties |
| 02/01/2006 | EP1620060A2 Methods and devices for the sustained release of multiple drugs |
| 02/01/2006 | EP1620059A2 Delivery systems of homogeneous, thermoreversible gel film containing kappa-2 carrageenan |
| 02/01/2006 | EP1620058A2 Composition for improving cognition and memory |
| 02/01/2006 | EP1619962A1 Composition for oral administration containing capsaicinoids |
| 02/01/2006 | EP1619952A2 Tolerance to graft prior to thymic regeneration |
| 02/01/2006 | EP1619948A1 Sustituted imidazolopyrazine and triazolopyrazine derivatives: gabaa receptor ligands |
| 02/01/2006 | EP1619947A2 Antibacterial methods and compositions |
| 02/01/2006 | EP1521535B1 Improved bulking agent composition |